Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BiDil Approval In Blacks Is Step Toward Personalized Medicine, FDA Says

Executive Summary

The approval of NitroMed's BiDil for treatment of heart failure in self-identified blacks is a step in the direction of drugs based on patient characteristics

You may also be interested in...



Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says

Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested

Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says

Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested

NitroMed/NAACP alliance

NitroMed provides a $1.5 mil. grant to the National Association for the Advancement of Colored People to develop "health advocacy initiatives towards equal access to quality healthcare," the firm announces Dec. 14. Among other initiatives, the grant will support the development of a "consensus paper on the state of African American healthcare and the impact of Medicare" and an Advocacy Action Plan for the NAACP National Health Leadership Committee. NitroMed markets BiDil (isosorbide dinitrate/hydralazine), which was approved in June for treatment of heart failure in self-identified black patients, and is the first therapy indicated for a specific ethnic population (1"The Pink Sheet" June 27, 2005, p. 5)...

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel